Sorrento Therapeutics, Inc. (OTCMKTS:SRNEQ) is a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer, pain management, autoimmune disorders and infectious diseases. Leveraging a proprietary antibody discovery engine and a suite of small-molecule, antibody-drug conjugate and cell therapy platforms, Sorrento seeks to advance a diversified pipeline of immuno-oncology candidates alongside treatments for acute and chronic pain.
The company’s pipeline includes antibody candidates derived from its G-MAB™ library, efforts to develop resiniferatoxin-based pain therapeutics licensed to Scilex Pharmaceuticals, and a variety of cell-based approaches such as CAR-T and exosome-based products. In addition, Sorrento has investigated small-molecule kinase inhibitors, including the BTK inhibitor abivertinib for inflammatory and viral indications, and has explored topical formulations like the ZTlido™ lidocaine patch.
Founded in 2009 and headquartered in San Diego, California, Sorrento operates research and development facilities in both North America and Asia. The company was established by Dr. Henry Ji, who serves as Chairman, Chief Executive Officer and Chief Scientific Officer, guiding its strategy to integrate cutting-edge discovery platforms with translational development.
Through strategic collaborations with academic institutions and industry partners, Sorrento Therapeutics aims to accelerate the clinical advancement and commercialization of its candidates across global markets. Its efforts span discovery research, preclinical validation and early-to-midstage clinical trials in an effort to address unmet medical needs in oncology, pain and inflammatory diseases.
AI Generated. May Contain Errors.
Free SRNEQ Stock Alerts